Adherence And Persistence Among Patients With Type 2 Diabetes Initiating Dulaglutide Sompared With S

Utilizing claims from the HealthCore Integrated Research Database, researchers sought to compare 6‐month adherence, persistence and treatment patterns among patients initiating once‐weekly glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dulaglutide vs semaglutide, and dulaglutide vs exenatide BCise. Patients aged ≥ 18 years, with T2D, ≥ 1 claim for dulaglutide, semaglutide or exenatide BCise during the index period February 2018 to December 2018 (index date = earliest GLP‐1RA fill date), no claim for GLP‐1RAs in the 6‐month pre‐index period, and continuous enrolment 6 months pre‐ and post‐index have been involved. Dulaglutide users were propensity‐matched 1:1 to users of semaglutide (3,852 pairs) or exenatide BCise (1,879 pairs). At 6‐month follow‐up, relative to matched patients initiating either semaglutide or exenatide BCise, a higher proportion of patients starting dulaglutide were adherent to and persistent with their treatment.

​

Source